APRE Aprea Therapeutics

Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548

Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548
EN
07/10/2020

Underlying

APREAprea Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aprea Therapeutics

 PRESS RELEASE
Free
APRE Aprea Therapeut...

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Pri...

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement Funding will support ongoing development of APR-1051, including expansion into selected patient populations where WEE1 mechanism is well suited DOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the closing of its previously announced oversubscribed private pla...

April 1, 2026 1 EN
Wedbush Research
  • Wedbush Research
PRGS PROGRESS SOFTWARE CORPORATION
ACRS ACLARIS THERAPEUTICS INC.
CCRN CROSS COUNTRY HEALTHCARE INC.
ANAB ANAPTYSBIO INC.
AAPL APPLE INC.
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
VRDN VIRIDIAN THERAPEUTICS INC
VOR VOR BIOPHARMA
BUR BURFORD CAPITAL
TMC THE METALS COMPANY INC
PEPG PEPGEN INC
BCAX BICARA THERAPEUTICS INC.
EIKN EIKON THERAPEUTICS INC
03/31/26 March 31, 2026 1 EN
Geoffrey Von Der Ahe ... (+2)
  • Geoffrey Von Der Ahe
  • Robert Driscoll
APRE APREA THERAPEUTICS
03/30/26 March 30, 2026 1 EN
 PRESS RELEASE
Free
APRE Aprea Therapeut...

Aprea Therapeutics Announces Oversubscribed $30 Million Private Placem...

Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement Financing led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Management and additional new and existing investors DOYLESTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that it has entered into a securities purchase agreement for an oversubscr...

March 30, 2026 1 EN
 PRESS RELEASE
Free
APRE Aprea Therapeut...

Aprea Therapeutics Highlights Positive Emerging Clinical Activity for ...

Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial Confirmed partial response at 220 mg indicates anti-tumor activity of APR-1051 in biomarker-defined cancersEarly clinical data suggest the potential of APR-1051 as a best-in-class WEE1 inhibitorEmerging clinical proof of concept responses without class-limiting toxicity to date support Aprea’s development strategy of differentiated WEE1 inhibition with an improved therapeutic indexA further update from the trial is expecte...

March 30, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch